What is a complete response letter?
A complete response letter means the FDA cannot approve an application in its current form. On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received this letter for Akeso’s ivonescimab. The 438-patient HARMONi trial’s primary overall survival p=0.057 missed the prespecified 0.0448 threshold; the decision concerns the submitted lung cancer indication.
| Measure | Reported result | Basis |
|---|---|---|
| General meaning | Application cannot be approved in its current form | FDA explanation published July 10, 2025 |
| Deficiencies | Set out in the letter | FDA may recommend steps to address them |
| Ivonescimab announcement | November 15, 2026 | Summit company statement |
| Reported efficacy issue | Statistically significant overall survival benefit not demonstrated | Submitted indication; not a decision on every potential use |
Ivonescimab after the FDA letter
HARMONi reported median overall survival of 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.
Sources
Read the full analysis
FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026